Trinity Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Trinity Biotech generated cash of -$11,557,000, which is less than the previous year. Cash used in financing activities reached the amount of -$16,042,000 last year. Net change in cash is therefore -$2,887,000.
Cash Flow
| 2014 | 15.75M | -23.93M | -5.03M |
|---|---|---|---|
| 2015 | 12.33M | -22.71M | 103.23M |
| 2016 | 13.77M | -22.27M | -16.33M |
| 2017 | 12.11M | -16.36M | -15.24M |
| 2018 | 6.93M | -17.28M | -16.97M |
| 2019 | 5.47M | -15.35M | -3.99M |
| 2020 | 23.75M | -10.19M | -2.71M |
| 2021 | 13.23M | -8.69M | -6.01M |
| 2022 | -921K | -5.97M | -12.32M |
| 2023 | -11.55M | 24.75M | -16.04M |
TRIB Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 6.57M | 25.91M | 27.32M | 16.4M | 30.27M | 57.60M | 77.10M | 101.95M | 9.10M | 22.31M |
Operating activities | ||||||||||
Net income | -24.01M | -41.00M | 875K | -6.38M | 12.19M | 13.07M | 12.76M | 16.24M | 19.85M | 22.02M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.77M | 2.33M | 2.74M | 3.07M | 4.89M | 4.12M | 5.19M | 6.13M | 5.64M | 4.49M |
Stock-based compensation expense | 2.06M | 1.75M | 1.1M | 792K | 758K | 0 | 928K | 1.41M | 1.55M | 1.49M |
| Deferred income tax benefit | 2.06M | 1.75M | 1.1M | 792K | 758K | 0 | 928K | 1.41M | 1.55M | 1.49M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.04M | -966K | 6.23M | -2.48M | 445K | -5.96M | -2.36M | 738K | -2.34M | -1.92M |
Inventories | -971K | -877K | -4.40M | -3.41M | -2.95M | 1.98M | -2.46M | -3.62M | -2.33M | -4.48M |
Accounts payable | -2.76M | 181K | -7.59M | 4.99M | 151K | -3.41M | 2.01M | 1.27M | -3.32M | 624K |
Cash generated by operating activities | -11.55M | -921K | 13.23M | 23.75M | 5.47M | 6.93M | 12.11M | 13.77M | 12.33M | 15.75M |
Investing activities | ||||||||||
Purchases Of Investments | -700K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -803K | -5.97M | -8.69M | -10.19M | -15.35M | -17.28M | -16.36M | -22.27M | -22.71M | -23.93M |
Acquisitions Net | 28.16M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 24.75M | -5.97M | -8.69M | -10.19M | -15.35M | -17.28M | -16.36M | -22.27M | -22.71M | -23.93M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 25.33M | 0 | 0 | 0 | 0 | 0 | 857K | 2.94M | 3.64M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.09M | -5.03M |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -434K | -7.79M | -9.32M | 0 | 0 |
Repayments of term debt | -7.36M | -27.04M | -2.93M | -3.24M | -3.53M | -12.41M | -244K | -282K | 116.35M | 0 |
Cash used in financing activities | -16.04M | -12.32M | -6.01M | -2.71M | -3.99M | -16.97M | -15.24M | -16.33M | 103.23M | -5.03M |
Net Change In Cash | -2.88M | -19.33M | -1.41M | 10.92M | -13.87M | -27.33M | -19.50M | -24.84M | 92.85M | -13.21M |
Cash at end of period | 3.69M | 6.57M | 25.91M | 27.32M | 16.4M | 30.27M | 57.60M | 77.10M | 101.95M | 9.10M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |